关于肝细胞癌的经手术组合疗法的当前观点
Takahiro Nishio1, Tomoaki Yoh1, Hiroto Nishino1
1Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Liver cancer
|June 18, 2025
概括
结合系统性疗法,如氨酸激酶抑制剂 (TKI) 和免疫瘤学 (IO) 与局部区域性疗法 (LRT),对晚期肝细胞癌 (HCC) 显示出有前途. 这种多学科的方法旨在改善治疗意图切除的患者的治疗结果.
科学领域:
- 肝胆道手术 肝胆道手术
- 医学瘤学 医学瘤学
- 干预性放射学 干预性放射学
背景情况:
- 肝细胞癌 (HCC) 治疗已经通过新的全身疗法取得了进展,包括受体氨酸激酶抑制剂 (TKI) 和免疫瘤学 (IO) 剂.
- 将全身疗法与TACE,HAIC和RT等局部区域疗法 (LRT) 结合起来,可以增强晚期HCC的抗瘤效果.
- 这些进展正在推动多学科治疗的发展,将全身疗法和LRT结合起来,以改善切除结果和长期预后.
研究的目的:
- 探索治疗肝细胞癌 (HCC) 的术后组合疗法的潜力.
- 研究系统疗法 (TKI和/或IO) 与LRT (TACE,HAIC或RT) 的整合,以治疗性目的进行外科切除或切除.
- 解决需要基于证据的指导选择标准和最佳方案的需要,在HCC的术后组合疗法.
主要方法:
- 对HCC的系统疗法 (TKI,IO) 和局部区域疗法 (TACE,HAIC,RT) 的当前进展进行审查.
- 分析新兴的术后组合疗法概念,整合系统和局部区域的模式.
- 探索对HCC的瘤切除能力的定义,以指导外科手术期间方案的开发.
主要成果:
- 术后组合疗法正在获得关注,作为HCC多学科治疗意图切除或切除的策略.
- 系统疗法和LRT的结合为最初无法切除或边缘切除的HCC患者提供了潜在的好处.
- 需要进一步的研究来确定这些复杂的治疗方案的选择标准和最佳方案.
结论:
- 术后组合疗法有望改善晚期HCC患者的长期预后,特别是那些最初无法切除或有高复发风险的患者.
- 系统疗法和LRT在术后框架中的整合是HCC管理中未来研究和临床应用的关键领域.
- 确定瘤切除能力对于建立术后组合治疗的指示和方案至关重要,旨在改善患者的治疗结果.
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
01:29Chronic Pancreatitis II: Collaborative Care
133
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
133
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K